[Congressional Record Volume 165, Number 198 (Wednesday, December 11, 2019)]
[House]
[Pages H10033-H10043]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
PROVIDING FOR CONSIDERATION OF H.R. 3, LOWER DRUG COSTS NOW ACT OF
2019; PROVIDING FOR CONSIDERATION OF H.R. 5038, FARM WORKFORCE
MODERNIZATION ACT OF 2019; AND PROVIDING FOR CONSIDERATION OF THE
CONFERENCE REPORT TO ACCOMPANY S. 1790, NATIONAL DEFENSE AUTHORIZATION
ACT FOR FISCAL YEAR 2020
Ms. SHALALA. Mr. Speaker, by direction of the Committee on Rules, I
call up House Resolution 758 and ask for its immediate consideration.
The Clerk read the resolution, as follows:
H. Res. 758
Resolved, That at any time after adoption of this
resolution the Speaker may, pursuant to clause 2(b) of rule
XVIII, declare the House resolved into the Committee of the
Whole House on the state of the Union for consideration of
the bill (H.R. 3) to establish a fair price negotiation
program, protect the Medicare program from excessive price
increases, and establish an out-of-pocket maximum for
Medicare part D enrollees, and for other purposes. The first
reading of the bill shall be dispensed with. All points of
order against consideration of the bill are waived. General
debate shall be confined to the bill and shall not exceed
four hours, with three hours equally divided among and
controlled by the respective chairs and ranking minority
members of the Committees on Education and Labor, Energy and
Commerce, and Ways and Means, and one hour equally divided
and controlled by the Majority Leader and the Minority Leader
or their respective designees. After general debate the bill
shall be considered for amendment under the five-minute rule.
In lieu of the amendments in the nature of a substitute
recommended by the Committees on Education and Labor, Energy
and Commerce, and Ways and Means
[[Page H10034]]
now printed in the bill, an amendment in the nature of a
substitute consisting of the text of Rules Committee Print
116-41, modified by the amendment printed in part A of the
report of the Committee on Rules accompanying this
resolution, shall be considered as adopted in the House and
in the Committee of the Whole. The bill, as amended, shall be
considered as the original bill for the purpose of further
amendment under the five-minute rule and shall be considered
as read. All points of order against provisions in the bill,
as amended, are waived. No further amendment to the bill, as
amended, shall be in order except those printed in part B of
the report of the Committee on Rules. Each such further
amendment may be offered only in the order printed in the
report, may be offered only by a Member designated in the
report, shall be considered as read, shall be debatable for
the time specified in the report equally divided and
controlled by the proponent and an opponent, shall not be
subject to amendment, and shall not be subject to a demand
for division of the question in the House or in the Committee
of the Whole. All points of order against such further
amendments are waived. At the conclusion of consideration of
the bill for amendment the Committee shall rise and report
the bill, as amended, to the House with such further
amendments as may have been adopted. The previous question
shall be considered as ordered on the bill, as amended, and
on any further amendment thereto to final passage without
intervening motion except one motion to recommit with or
without instructions.
Sec. 2. Upon adoption of this resolution it shall be in
order to consider in the House the bill (H.R. 5038) to amend
the Immigration and Nationality Act to provide for terms and
conditions for nonimmigrant workers performing agricultural
labor or services, and for other purposes. All points of
order against consideration of the bill are waived. In lieu
of the amendment in the nature of a substitute recommended by
the Committee on the Judiciary now printed in the bill, an
amendment in the nature of a substitute consisting of the
text of Rules Committee Print 116-42, modified by the
amendment printed in part C of the report of the Committee on
Rules accompanying this resolution, shall be considered as
adopted. The bill, as amended, shall be considered as read.
All points of order against provisions in the bill, as
amended, are waived. The previous question shall be
considered as ordered on the bill, as amended, and on any
further amendment thereto, to final passage without
intervening motion except: (1) one hour of debate equally
divided and controlled by the chair and ranking minority
member of the Committee on the Judiciary; and (2) one motion
to recommit with or without instructions.
Sec. 3. Upon adoption of this resolution it shall be in
order to consider the conference report to accompany the bill
(S. 1790) to authorize appropriations for fiscal year 2020
for military activities of the Department of Defense, for
military construction, and for defense activities of the
Department of Energy, to prescribe military personnel
strengths for such fiscal year, and for other purposes. All
points of order against the conference report and against its
consideration are waived. The conference report shall be
considered as read. The previous question shall be considered
as ordered on the conference report to its adoption without
intervening motion except: (1) one hour of debate; and (2)
one motion to recommit if applicable.
Sec. 4. The chair of the Permanent Select Committee on
Intelligence may insert in the Congressional Record not later
than December 13, 2019, such material as he may deem
explanatory of intelligence authorization measures for the
fiscal years 2018, 2019, and 2020.
Sec. 5. It shall be in order at any time through the
legislative day of December 20, 2019, for the Speaker to
entertain motions that the House suspend the rules as though
under clause 1 of rule XV. The Speaker or her designee shall
consult with the Minority Leader or his designee on the
designation of any matter for consideration pursuant to this
section.
Sec. 6. The requirement of clause 6(a) of rule XIII for a
two-thirds vote to consider a report from the Committee on
Rules on the same day it is presented to the House is waived
with respect to any resolution reported through the
legislative day of December 20, 2019.
Sec. 7. On any legislative day of the first session of the
One Hundred Sixteenth Congress after December 12, 2019--
(a) the Journal of the proceedings of the previous day
shall be considered as approved; and
(b) the Chair may at any time declare the House adjourned
to meet at a date and time, within the limits of clause 4,
section 5, article I of the Constitution, to be announced by
the Chair in declaring the adjournment.
Sec. 8. On any legislative day of the second session of
the One Hundred Sixteenth Congress before January 7, 2020--
(a) the Speaker may dispense with organizational and
legislative business;
(b) the Journal of the proceedings of the previous day
shall be considered as approved if applicable; and
(c) the Chair may at any time declare the House adjourned
to meet at a date and time, within the limits of clause 4,
section 5, article I of the Constitution, to be announced by
the Chair in declaring the adjournment.
Sec. 9. The Speaker may appoint Members to perform the
duties of the Chair for the duration of the periods addressed
by sections 7 and 8 of this resolution as though under clause
8(a) of rule I.
Sec. 10. Each day during the periods addressed by sections
7 and 8 of this resolution shall not constitute a calendar
day for purposes of section 7 of the War Powers Resolution
(50 U.S.C. 1546).
Sec. 11. Each day during the periods addressed by sections
7 and 8 of this resolution shall not constitute a legislative
day for purposes of clause 7 of rule XIII.
Sec. 12. Each day during the periods addressed by sections
7 and 8 of this resolution shall not constitute a legislative
day for purposes of clause 7 of rule XV.
The SPEAKER pro tempore. The gentlewoman from Florida is recognized
for 1 hour.
Ms. SHALALA. Mr. Speaker, for the purpose of debate only, I yield the
customary 30 minutes to the gentleman from Texas, pending which I yield
myself such time as I may consume. During consideration of this
resolution, all time yielded is for the purpose of debate only.
General Leave
Ms. SHALALA. Mr. Speaker, I ask unanimous consent that all Members
have 5 legislative days in which to revise and extend their remarks.
The SPEAKER pro tempore. Is there objection to the request of the
gentlewoman from Florida?
There was no objection.
Ms. SHALALA. Mr. Speaker, on Monday, the Rules Committee met and
reported a rule, House Resolution 758, providing for the consideration
of H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 5038,
the Farm Workforce Modernization Act; and the conference report to
accompany S. 1790, the National Defense Authorization Act for Fiscal
Year 2020.
The rule provides for consideration of H.R. 3 under a structured rule
and makes in order 12 amendments, including the Republican substitute.
The rule provides 4 hours of general debate, with 3 hours equally
divided among and controlled by the chairs and the ranking minority
members of the Committees on Education and Labor, Energy and Commerce,
and Ways and Means, and 1 hour equally divided and controlled by the
majority leader and minority leader. The rule also provides a motion to
recommit.
The rule provides for consideration of H.R. 5038 under a closed rule,
with 1 hour of debate equally divided and controlled by the chair and
the ranking member of the Judiciary Committee. It also provides for a
motion to recommit.
The rule further provides for consideration of the conference report
to accompany S. 1790 with 1 hour of debate and a motion to recommit, if
applicable.
The rule also authorizes the chair of the Intelligence Committee to
insert in the Congressional Record explanatory statements as he deems
necessary.
Finally, the rule provides housekeeping items to close out the first
session of this Congress, such as same-day authority, suspension
authority, district work period instructions, and language to convene
the Second Session of the 116th Congress on January 7.
Mr. Speaker, I rise today in strong support of the bills in this
rule.
Mr. Speaker, only a few times in our history has Congress come
together to pass legislation to dramatically improve the life of every
American--Social Security, Medicare, Medicaid, the Children's Health
Insurance Program, the Americans with Disabilities Act, Medicare's drug
benefit, and, of course, the Affordable Care Act. We change lives. We
save lives.
Now, we continue that work with H.R. 3, the Elijah E. Cummings Lower
Drug Costs Now Act. The passage of this bill will take this legislation
forward to join those momentous commitments to the health and security
of all Americans.
Mr. Speaker, we pay more for our prescription drugs than any other
country on Earth. We have made incredible advances in medical science
and developed cures not only for our own people but also for the rest
of the world. Yet, even when our own researchers and scientists have
dedicated their lives to creating lifesaving drugs, too many of our
fellow Americans can't afford to benefit from their brilliance.
In the United States today, a disease or a chronic condition can
force you into bankruptcy or require you to choose between paying for
medicine or paying for food or rent.
[[Page H10035]]
Mr. Speaker, H.R. 3 makes fundamental reforms to reduce drug prices
to keep the cost hikes to no more than inflation and to limit out-of-
pocket costs for those on Medicare, employer plans, and private health
insurance.
To help secure these patient protections, we will require our
government to negotiate prices directly with drug companies.
Mr. Speaker, I served as Secretary of Health and Human Services for 8
years in the Clinton administration. I repeatedly asked for the ability
to negotiate with drug companies.
Only drug companies get to come to Medicare and set their own prices.
{time} 1245
Hospitals don't get to do that; doctors don't get to do that; home
healthcare agencies don't get to do that; and medical equipment
providers don't get to do that.
Negotiation is the hallmark of good governance and a standard feature
of government policy.
Mr. Speaker, we negotiate for everything, including military
equipment and work with contractors. If we can negotiate for big ships,
then we can negotiate for little pills. It is only drug companies that
are able to write themselves a blank check from our taxpayers. Our
legislation ends that practice.
Now is the time to join every other country on Earth in allowing our
government to bargain for better prices and to put a cap on our out-of-
pocket costs.
As citizens, we have always been willing to subsidize poorer
countries. But subsidizing England, France, Canada, Germany, Australia,
Japan, Sweden, Norway, and Denmark is not our responsibility. We are
not their deep pockets.
Mr. Speaker, we should not pay substantially more for the same
medicines than people in those countries. The current broken system is
costing our families and businesses hundreds of billions of dollars. We
must not accept this waste or this unfairness any longer.
Our bill is a solid plan to reduce out-of-pocket healthcare costs for
every American, and it will create a huge savings for taxpayers.
These savings will allow us to make significant investments in the
extraordinary biomedical science institutions that foster innovation,
such as the National Institutes of Health and our great research
universities.
These savings will allow us to modernize Medicare hearing and vision
benefits and dental coverage.
This bill will expand our capacity for innovation and make drug
companies more efficient. H.R. 3 is a historic step forward, and it
will make all of our lives better.
Mr. Speaker, this rule also contains the Farm Workforce Modernization
Act of 2019. This bill empowers families to build lives in the United
States without the constant fear of being uprooted. It prioritizes the
well-being of immigrant families, many of whom provide essential
support for our Nation's agricultural sector. This bill is an important
step forward in improving our immigration system, in helping to make
sure that we treat everyone with compassion and dignity.
Finally, this rule also allows for consideration of the National
Defense Authorization Act conference report. The first NDAA under our
new Democratic majority fulfills one of Congress' crucial
constitutional duties: providing for the common defense of our Nation.
The final conference report delivers a wide-ranging list of
priorities the American people strongly support, such as paid parental
leave, the end of the widow's tax, better services for our men and
women in uniform, and protections for Dreamers.
This report is the product of months of hard work by Chairman Smith
and members of the committee and will undoubtedly keep our country
safe.
Mr. Speaker, I proudly support these historic steps forward. Let's
pass this rule and these bills.
Mr. Speaker, I reserve the balance of my time.
Mr. BURGESS. Mr. Speaker, I yield myself such time as I may consume,
and I thank Ms. Shalala for yielding me the customary 30 minutes.
Mr. Speaker, today we are considering a bill that does a lot of
things, and, if nothing else, this should be an object lesson on why
you don't leave everything to the last minute because, indeed, that is
what we have done in this year, this session of Congress. So we have
got a rule that has three fairly different bills contained.
We are considering a bill to reform the H-2A guest worker programs,
the National Defense Authorization Act conference report, and H.R. 3, a
bill that will limit American patients from treatments and cures of
tomorrow.
H.R. 5038, the Farm Workforce Modernization Act, allows aliens who
have worked in the United States for 180 days, are deportable, and have
been continually present to be granted certified agricultural work
status. The status may also be extended to a recipient's spouse and
children. Certified workers can then apply for a green card path to
citizenship, and they are not counted toward the statutory cap.
In addition, the bill would subject H-2A users to a private right of
action and will not provide long-term wage relief. While the H-2A guest
worker visa program arguably needs reform, this bill expands the
ability to obtain legal status without adequate requirements,
documentation, or protections for the H-2A program users.
Second, the National Defense Authorization Act is a bipartisan
agreement to provide for a 3.1 percent pay raise for our troops, reform
privatized military housing, continue rebuilding readiness, provide
security assistance to our allies, and hold the Pentagon accountable
through reports on auditability.
The bill also protects the homeland by including my language
requiring an effort to identify hostile International Mobile Subscriber
Identity catchers, known as stingrays, which are used to locate and spy
on Americans.
Last, the NDAA repeals the widow's tax and prohibits the use of a
chemical compound known as PFAS in firefighting foam after October
2024.
I am pleased that we were able to reach an agreement to maintain the
strongest military in the world.
Now, let's turn to H.R. 3, the third bill that is being contained in
this rather wide-ranging rule. This bill attempts to address the high
cost of drugs, a goal of which I am supportive, but this bill severely
limits patient access to potentially new lifesaving drugs.
Republicans have offered a substitute bill, H.R. 19, the Lower Costs,
More Cures Act of 2019, that includes bipartisan policies to lower drug
costs for Americans.
There are a lot of reasons that Members should support H.R. 19, which
will now be our amendment in the nature of a substitute. Since it is
H.R. 19, let me limit myself to 19 reasons.
One, H.R. 19 will lower drug costs for American patients, while
protecting access to new treatments and cures.
Two, H.R. 19 is bipartisan, including more than 40 drug pricing
policies that have passed through House and Senate committees this
year.
Three, H.R. 19 would pass--could pass--both Chambers of Congress and
be signed into law in calendar year 2019.
Four, H.R. 19 will cap out-of-pocket costs in Medicare part D for
seniors at $3,100 per year, ensuring protection from the high cost
encountered with prescription drugs.
Five, H.R. 19 saves money for patients and their families rather than
saving money just for the government.
Six, H.R. 19 includes policies such as the CREATES Act and pay-for-
delay to prevent pharmaceutical companies from gaming the system.
Seven, H.R. 19 promotes healthy competition for lower cost generics.
Eight, H.R. 19 corrects for the increased threshold it takes to reach
catastrophic coverage in part D, which is not yet fixed for plan year
2020. This bill will provide seniors with a refund in 2020 for costs
they should never have had to incur in the first place.
Nine, H.R. 19 strengthens transparency and accountability in the
existing drug pricing system.
Ten, H.R. 19 lowers the cost of insulin by capping the costs for
seniors in Medicare part D at $50 per month and adds additional
incentives for insurance to cover their fair share of insulin costs.
Eleven, H.R. 19 lowers the cost of drug administration by not paying
drastically more for the same service, whether it is provided in a
hospital or
[[Page H10036]]
other more traditionally expensive environments, the so-called site-
neutral provision.
Twelve, H.R. 19 establishes a new negotiator at the United States
Trade Representative to ensure that America is not subsidizing the
world's drug costs.
Thirteen, H.R. 19 makes permanent a threshold of 7.5 percent of the
adjusted gross income for purposes of the medical expense tax deduction
in the Internal Revenue Code. Recall that, under the Affordable Care
Act, this threshold was increased to 10 percent, which many seniors
found onerous. It was reduced in the passage of the Tax Cuts and Jobs
Act of 2017 to the threshold of 7.5 percent, but that threshold then
expires, and it goes and reverts back to the 10 percent threshold at
the end of this year. This would make that permanent.
Fourteen, H.R. 19 requires pricing information in direct-to-consumer
advertisements.
Fifteen, H.R. 19 cracks down on pharmacy benefit managers by
requiring more transparency in the reporting of aggregate rebates,
discounts, and other price concessions.
Sixteen, H.R. 19 helps access to prescription drugs in rural areas by
reforming direct and indirect remuneration fees, the so-called dreaded
DIR fee clawback that every community pharmacist dislikes so intensely.
Seventeen, H.R. 19 increases transparency into patient listings so
that manufacturers of generics and biosimilars will have adequate
information to enter the market.
Eighteen, H.R. 19 removes uncertainty at the pharmacy counter by
requiring insurance companies to provide pricing information to doctors
so that patients and their doctors can have discussions about what
medicine is best for them and what the cost will be.
Finally, number 19, H.R. 19 allows biomedical innovation to continue
to thrive. It does not abandon the success of the 21st Century Cures
bill. It lowers drug costs for Americans, while maintaining access to
drugs that exist now and ensuring that that access is sustained in the
future.
Mr. Speaker, there are many more than three reasons to oppose H.R. 3,
but let's limit ourselves to three reasons so compelling that, really,
you shouldn't need to go into any more.
Number one, the Congressional Budget Office, the Council of Economic
Advisers, and the California Life Sciences Association have found that
H.R. 3 will result in fewer drugs for Americans. There is no way to
predict what could be included in this fewer drugs. It could be the
cure for Alzheimer's; it could be the cure for ALS; or it could be the
cure for pancreatic cancer.
There is some disparity in the number of cures that would be lost
with the passage of this bill, but here is the central thesis: Every
organization that has looked at this has said that there will be fewer
drugs introduced after the passage of this bill.
{time} 1300
In addition, access to drugs that help or cure or maintain a healthy
life will be at risk. The six-referenced countries in H.R. 3 have 30 to
60 percent fewer new medications than the United States of America.
This is what is at stake today.
Number 2, H.R. 3 claims to negotiate drug prices, but with a 95
percent excise tax for manufacturers who fail to reach a price
agreement with the government, it is more akin to a hostage-taking and
then shooting the hostage.
There are concerns that this is unconstitutional under the Takings
Clause of the Constitution. This takeover of the entire drug industry
in the United States is not only bad policy but may be constitutionally
perilous.
Interestingly enough, when this bill was marked up in our committee,
one of our Members on the Republican side spoke to this issue, tried to
offer an amendment that would have provided severability, so that if
the law was found to be unconstitutional, that the part that was
unconstitutional could be struck down and the rest could stand. But for
whatever reason, the majority rejected that amendment and it was
defeated on a party line vote.
Number three, and this is critically important, H.R. 3 will never
become law. The majority leader of the other body has said that H.R. 3
is dead-on-arrival in the Senate. And President Trump has related how
H.R. 3 is not good for Americans.
I think it is important that we fight for a world where research into
life-threatening illnesses never ceases, no matter how many failures
occur before a cure is found.
Mr. Speaker, I urge opposition to the rule, opposition to the
underlying bill, H.R. 3, and I reserve the balance of my time.
Ms. SHALALA. Mr. Speaker, I thank the gentleman from Texas (Mr.
Burgess).
Mr. Speaker, I yield 2 minutes to the gentlewoman from California
(Ms. Lofgren), the distinguished chair of the Judiciary Subcommittee on
Immigration and Citizenship.
Ms. LOFGREN. Mr. Speaker, I am here to speak in support of the Farm
Workforce Modernization Act, an event that should be a cause of joy for
Members on both sides of the aisle and for America.
We have tried and failed for dozens of years to deal with the issue
of the farm workforce. We have never been able to get a majority vote
on the floor of this House. So this year, we tried a different
approach.
Starting last March, we had stakeholders, the United Farm Workers
Union, the growers and the farmers sit down together, listen to each
other, understand each other and what their needs were. They were
joined by a bipartisan group of members who cared about this issue, and
we came up with this bill, a compromise that does this:
It secures the status of the million or so farm workers who don't
have their proper documentation by allowing them to get a certified
agriculture worker visa that is renewable, and ultimately, if they
wish, after a significant period of time, to apply for legal permanent
residence. It streamlines the H-2A program, so it works better for
employers and actually works better for workers.
We stabilized the wages. We allowed the dairy industry to get access
to the H-2A program. We increased the availability of farmworker
housing while lowering the cost to employers.
And, finally, once this whole thing is implemented, we have always
believed that if you have a workable immigration system, you ought to
enforce it. And so we will implement E-Verify after full
implementation, but only for the Ag sector.
I would note that the Farm Labor Organizing Committee of the AFL-CIO,
UFW, Farmworker Justice, the Catholic Bishops--over 300 agricultural
organizations have asked that we pass this bill.
Mr. Speaker, I include in the Record a letter in support of the Farm
Workforce Modernization Act.
November 18, 2019.
Hon. Nancy Pelosi,
Speaker, House of Representatives,
Washington, DC.
Hon. Kevin McCarthy,
Minority Leader, House of Representatives,
Washington, DC.
Dear Speaker Pelosi and Minority Leader McCarthy: The
undersigned groups, representing a broad cross-section of
agriculture and its allies, urge you to advance the Farm
Workforce Modernization Act (H.R. 5038) through the House to
address the labor crisis facing American agriculture. A
stable, legal workforce is needed to ensure farmers and
ranchers have the ability to continue producing an abundant,
safe, and affordable food supply.
The effects of agriculture's critical shortage of labor
reach far beyond the farm gate, negatively impacting our
economic competitiveness, local economies, and jobs.
Economists have found that every farm worker engaged in high-
value, labor-intensive crop and livestock production sustains
two to three off-farm jobs. As foreign producers take
advantage of our labor shortage and gain market share,
America will export not only our food production but also
thousands of these farm-dependent jobs. Securing a reliable
and skilled workforce is essential, not only for the
agricultural industry but for the U.S. economy as a whole.
The House must pass legislation that preserves
agriculture's experienced workforce by allowing current farm
workers to earn legal status. For future needs, legislation
must include an agricultural worker visa program that
provides access to a legal and reliable workforce moving
forward. This visa program needs to be more accessible,
predictable, and flexible to meet the needs of producers,
including those with year-round labor needs, such as dairy
and livestock which currently do not have meaningful access
to any program.
While the bill does include a few provisions that raise
significant concerns for the agricultural community, we are
committed to working together throughout the legislative
process to fully address these issues. It is vital to move
the Farm Workforce Modernization Act (H.R. 5038) through the
House as a significant step in working to meet the
[[Page H10037]]
labor needs of agriculture, both now and in the future.
Sincerely,
African-American Farmers of California; AgCountry Farm
Credit Services; AgriBank FCB; Agribusiness Henderson County
(AgHC); Agricultural Council of California Agri-Mark, Inc.;
Alabama Farmers Cooperative; Alabama Nursery & Landscape
Association; Almond Alliance of California; Amalgamated Sugar
Company LLC; American AgCredit; American Agri-Women; American
Beekeeping Federation; American Mushroom Institute; American
Pistachio Growers; American Seed Trade Association
AmericanHort.
Arizona Cattle Feeders' Association; Arizona Landscape
Contractors Association; Arizona Nursery Association;
Arkansas Rice Growers Association; Associated Milk Producers
Inc.; Association of Virginia Potato and Vegetable Growers;
Aurora Organic Dairy; AZ Farm & Ranch Group; Battlefield
Farms, Inc.; Bipartisan Policy Center Action; Bongards'
Creameries; Butte County Farm Bureau; California Ag
Irrigation Association; California Alfalfa and Forage
Association; California Apple Commission.
California Avocado Commission; California Bean Shippers
Association; California Blueberry Commission; California
Canning Peach Association; California Cherry Growers and
Industry Association; California Citrus Mutual; California
Dairies, Inc.; California Farm Bureau Federation; California
Fig Advisory Board; California Fresh Fruit Association;
California Grain and Feed Association; California League of
Food Producers; California Pear Growers; California Prune
Board; California Seed Association; California State
Beekeepers Association.
California State Floral Association; California Sweet
Potato Council; California Tomato Growers Association;
California Walnut Commission; California Warehouse
Association; California Wheat Growers Association; California
Women for Agriculture; Cayuga Milk Ingredients; Central
Valley Ag; Cherry Marketing Institute; Chobani; Clif Bar &
Company; CoBank; Colorado Dairy Farmers; Colorado Nursery &
Greenhouse Association.
Colorado Potato Legislative Association; Compeer Financial;
Cooperative Milk Producers Association; Cooperative Network
Dairy Farmers of America, Inc.; Dairy Producers of New
Mexico; Dairy Producers of Utah; Del Mar Food Products,
Corp.; Driscoll's; Edge Dairy Farmer Cooperative; Ellsworth
Cooperative Creamery; Empire State Potato Growers; Far West
Agribusiness Association; Farm Credit East; Farm Credit
Illinois.
Farm Credit Services of America; Farm Credit West;
FarmFirst Dairy Cooperative; First District Association;
Florida Agri-Women; Florida Blueberry Growers Association;
Florida Citrus Mutual; Florida Fruit & Vegetable Association;
Florida Nursery, Growers, and Landscape Association; Florida
Strawberry Growers Association; Florida Tomato Exchange; Food
Northwest; Food Producers of Idaho; Foremost Farms USA;
Fresno County Farm Bureau.
Frontier Farm Credit; Fruit Growers Marketing Association;
Fruit Growers Supply; Georgia Green Industry Association;
Glanbia Nutritionals; Grapeman Farms; GreenStone Farm Credit
Services; Grower-Shipper Association of Central California;
GROWMARK; Gulf Citrus Growers Association; Hop Growers of
Washington; Idaho Alfalfa & Clover Seed Commission; Idaho
Alfalfa & Clover Seed Growers Association; Idaho Apple
Commission; Idaho Association of Commerce and Industry.
Idaho Association of Highway Districts; Idaho Association
of Soil Conservation Districts; Idaho Bankers Association;
Idaho Cattleman's Association; Idaho Chamber Alliance; Idaho
Dairymen's Association; Idaho Eastern Oregon Seed
Association; Idaho Grain Producers Association; Idaho Grower
Shipper Association; Idaho Hop Growers; Idaho Milk Products;
Idaho Mint Growers Association; Idaho Noxious Weed Control
Association; Idaho Nursery & Landscape Association; Idaho
Onion Growers Association.
Idaho Potato Commission; Idaho State Grange; Idaho
Sugarbeet Growers Association; Idaho Water Users Association;
Idaho Wool Growers; Idahoan Foods LLC; Idaho-Oregon Fruit and
Vegetable Association; Illinois Green Industry
Association; International Dairy Food Association; Iowa
Institute for Cooperatives; Iowa State Dairy Association;
J.R. Simplot Company; Kansas Cooperative Council; Kansas
Dairy Association; Kanza Cooperative Association; Kings
County Farm Bureau.
Land O'Lakes, Inc.; Lone Star Milk Producers; Madera County
Farm Bureau; Maine Landscape and Nursery Association; Maine
Potato Board; Maryland & Virginia Milk Producers Cooperative
Association; Maryland Nursery, Landscape, & Greenhouse
Association; Massachusetts Nursery and Landscape Association,
Inc.; MBG Marketing; Mendocino County Farm Bureau; Merced
County Farm Bureau; Michigan Agri-Business Association;
Michigan Apple Association; Michigan Asparagus Advisory
Board.
Michigan Bean Shippers; Michigan Cider Association;
Michigan Greenhouse Grower Council; Michigan Milk Producers
Association; Michigan Nursery & Landscape Association;
Michigan State Horticultural Society; Midwest Dairy
Coalition; Mid-West Dairymen's Company; Milk Producers
Council; Milk Producers of Idaho; Minnesota Area II Potato
Council; Minnesota Milk Producers Association; Minnesota
Nursery & Landscape Association; Missouri Rice Research and
Merchandising Council; Montana Nursery & Landscape
Association.
Monterey County (CA) Farm Bureau; Mount Joy Farmers
Cooperative Association; Napa County Farm Bureau; National
All-Jersey; National Association of Produce Market Managers;
National Council of Agricultural Employers; National Council
of Farmer Cooperatives; National Farmers Union; National
Grange; National Immigration Forum; National Milk Producers
Federation; National Onion Association; National Potato
Council; National Watermelon Association; Nebraska State
Dairy Association.
New American Economy; New England Apple Council; New
England Farmers Union; New York Apple Association; New York
Farm Bureau Federation; New York State Berry Growers
Association; New York State Flower Industries; New York State
Vegetable Growers Association; Nezperce Prairie Grass Growers
Association; Nisei Farmers League; North American Blueberry
Council; North Carolina Nursery & Landscape Association;
North Carolina Potato Association; Northeast Dairy Farmers
Cooperatives.
Northeast Dairy Foods Association, Inc.; Northeast Dairy
Producers Association; Northern Plains Potato Growers
Association; Northern Virginia Nursery & Landscape
Association; Northwest Ag Co-op Council; Northwest Dairy
Association/Darigold; Northwest Farm Credit Services;
Northwest Horticultural Council; Ohio Apple Marketing
Program; Ohio Dairy Producers Association; Ohio Nursery &
Landscape Association; Olive Growers Council of California;
Oneida-Madison Milk Producers Cooperative Association; Orange
County Farm Bureau; Oregon Association of Nurseries.
Oregon Dairy Farmers Association; Oregon Potato Commission;
Pacific Coast Producers; Pacific Egg and Poultry Association;
Pacific Seed Association; Pennsylvania Co-operative Potato
Growers; Pennsylvania Landscape & Nursery Association; Plant
California Alliance; POM Wonderful; Porterville Citrus;
Potato Growers of America; Potato Growers of Idaho; Potato
Growers of Michigan; Prairie Farms Dairy, Inc.; Premier Milk
Inc.
Produce Marketing Association; Professional Dairy Managers
of Pennsylvania; RBI Packing LLC; Reiter Affiliated
Companies; Richard Bagdasarian, Inc.; Riverside County Farm
Bureau; Rocky Mountain Farmers Union; San Diego County Farm
Bureau; San Mateo County Farm Bureau; Santa Clara County Farm
Bureau; Santa Cruz County Farm Bureau; Scioto Cooperative
Milk Producers' Association; Select Milk Producers, Inc.;
Seneca Foods Corporation; Sierra Citrus Association.
Snake River Sugar Company; Solano County Farm Bureau;
Sonoma County Farm Bureau; South Dakota Association of
Cooperatives; South Dakota Dairy Producers; South East Dairy
Farmers Association; Southeast Milk Inc.; Southern States
Cooperative; St. Albans Cooperative Creamery, Inc.;
Stanislaus County Farm Bureau; State Horticultural
Association of Pennsylvania; Summer Prize Frozen Foods;
Sunkist Growers; Sun-Maid Growers of California; Sunsweet
Growers, Inc.
Tennessee Nursery & Landscape Association; Texas
Agricultural Cooperative Council; Texas Association of
Dairymen; Texas Citrus Mutual; Texas International Produce
Association; Texas Nursery & Landscape Association; The
National Association of State Departments of Agriculture; The
SF Market and San Francisco Produce Association; Tillamook
County Creamery Association; Tree Top, Inc.; Tulare County
Farm Bureau; U.S. Apple Association; U.S. Rice Producers
Association; United Ag; United Dairymen of Arizona; United
Egg Producers; United Fresh Produce Association.
United Onions, USA; United Potato Growers of America;
Upstate Niagara Cooperative, Inc.; Utah Farmers Union; Utah
Horticulture Society; Valley Fig Growers; Ventura County
Agricultural Association; Ventura Pacific; Vermont Dairy
Producers Alliance; Virginia Apple Growers Association;
Virginia Nursery & Landscape Association; Virginia State
Dairymen's Association; Visalia Citrus Packing Group, Inc.;
WA Wine Institute; Washington Growers League; Washington
State Dairy Federation.
Washington State Nursery & Landscape Association;
Washington State Potato Commission; Washington State Tree
Fruit Association; Wawona Frozen Foods; West Virginia Nursery
& Landscape Association; Western Growers Association; Western
States Dairy Producers Association; Western United Dairies;
Wine Institute; WineAmerica; Wisconsin Dairy Business
Association; Wisconsin Potato & Vegetable Growers
Association; Wonderful Citrus; Wonderful Orchards; Yuma Fresh
Vegetable Association.
The SPEAKER pro tempore. The time of the gentlewoman has expired.
Ms. SHALALA. Mr. Speaker, I yield an additional 15 seconds to the
gentlewoman.
Ms. LOFGREN. Mr. Speaker, I would like to thank my colleagues, Mr.
Newhouse, Mr. Simpson, Mr. LaMalfa, Mr. Diaz-Balart, Mr. Panetta, Mr.
Costa, Mr. Correa, Ms. Escobar, Mr. Peterson--I am going to get in
trouble because there are more people than I can mention in the 15
seconds, but this has been a very large bipartisan effort.
[[Page H10038]]
It should be a model on how we can legislate and get something done for
the American people.
Ms. SHALALA. Mr. Speaker, I reserve the balance of my time.
Mr. BURGESS. Mr. Speaker, I yield 2 minutes to the gentleman from
Florida (Mr. Diaz-Balart), a valuable member of the Committee on
Appropriations.
Mr. DIAZ-BALART. Mr. Speaker, I rise today in support of the
underlying bill, the Agriculture Workforce Modernization Act.
Now, when you read the title, maybe folks will think that this is
only an agriculture bill. But in reality, this bill also helps to deal
with a vital national security issue: A stable supply of agricultural
goods produced here in the United States of America. Not by a foreign
power who does not have our interests in mind, and could use our food
security as a weapon, but, no, agricultural products grown here by
patriotic American farmers.
And this issue will not happen by itself. The H-2A system that our
farmers now use to get their workforce--frankly, when they are not able
to find American workers--is absolutely broken. It is antiquated, and
it is just not responsive to the changing needs of the patriotic
American farmer.
That is why Members from both sides of the aisle have come together
with over 300 farming organizations to draft a bill that ensures that
in the United States of America those who grow our food will be able to
continue to grow our food and have the adequate workforce that they
need.
No bill is perfect, and this one isn't perfect either. But, again,
this bill, if it moves forward and gets to the President's desk--and
this bill, if it moves forward, can be changed and tweaked to make sure
that it gets to the President's desk--and if we don't do that, we will
be, frankly, letting down our farmers, letting them down one more time,
and, again, opening up the door to a national security threat that we
do not need to allow to happen.
I urge my colleagues to vote ``yes'' on the underlying bill.
But before I yield back, Mr. Speaker, I would like to thank a few
people. Some have already been thanked: Mike Carlton from Florida Fruit
& Vegetable Association, for his work to ensure that Florida's
agricultural interests were represented in the negotiations.
I also would like to thank a few staffers: I thank David Shahoulian
from the Committee on the Judiciary who has been amazing over these
years; Carrie Meadows from Representative Newhouse's staff; and also
Cesar Gonzalez, my chief of staff, who has been invaluable, by the way,
in years of working to try to have solutions to an issue that we all
know needs to take place.
Mr. BURGESS. Mr. Speaker, I reserve the balance of my time.
Ms. SHALALA. Mr. Speaker, I thank the gentleman from Florida (Mr.
Diaz-Balart), my colleague for representing Florida in the negotiations
so well.
Mr. Speaker, I yield 1 minute to the gentleman from New Hampshire
(Mr. Pappas).
Mr. PAPPAS. Mr. Speaker, when I travel around New Hampshire asking
constituents what is on their minds, there is no topic more urgent or
more personal than combatting the skyrocketing cost of prescription
drugs.
I have heard from a senior who is unable to retire because his life
is dependent on drugs that cost $3,000 out-of-pocket.
I have heard from a mother who shares a painful chronic condition
with her daughter and has to decide every month whose prescription to
fill because she can't fill both on her fixed income.
Americans can no longer afford Big Pharma's runaway costs. That is
why I am proud to support H.R. 3, which makes historic reforms to drive
down the cost of prescription drugs while expanding and strengthening
Medicare. This package also includes my Advancing Enrollment and
Reducing Drug Costs Act, which makes prescription drugs more accessible
for seniors.
My provision assists low-income seniors by automatically enrolling
them in Medicare Part D's subsidy program, ensuring they receive this
benefit without jumping through bureaucratic hoops.
It is time to deliver transformational change and pass H.R. 3 to
ensure the health and well-being of the American people.
Ms. SHALALA. Mr. Speaker, I reserve the balance of my time.
Mr. BURGESS. Mr. Speaker, I yield myself 30 seconds.
Mr. Speaker, this bill, H.R. 3, runs the risk of quickly stifling
innovation in the new drug space. A preliminary Congressional Budget
Office analysis of this bill has stated that it would result in 15
fewer new drugs coming on the market over the next 10 years, and we all
know drugs are in the pipeline for much longer than that. The actual
pipeline to deliver new product is 14 years, so it is that second 10
years where the real risk of this bill becomes apparent.
The cure for Alzheimer's may be one of those ones that is included in
that list of drugs that are never developed in the first place. That is
why we need to defeat H.R. 3.
Mr. Speaker, I reserve the balance of my time.
Ms. SHALALA. Mr. Speaker, I yield 2 minutes to the gentleman from
Vermont (Mr. Welch).
Mr. WELCH. Mr. Speaker, today, the House is going to have an
opportunity to do something that has long-needed to be done and will
benefit every single American in every single business that is
providing health insurance for their valued employees. We have a chance
to pass the Elijah E. Cummings Lower Drug Costs Now Act.
Here is what is significant about it, but first a word about Elijah:
In April of 2017, Elijah and I went to the White House and met with
President Trump, who said all the right things:
``Why are we getting ripped off by Pharma?''
``Why can't we import safe medications?''
``Why can't we lower costs?''
Today, President Trump, we are going to do it.
Two things are finally being done:
First, the House of Representatives, on behalf of all consumers, is
going to allow the Health and Human Services secretary to negotiate
prices, not just pay the rip-off prices demanded.
Second, we are adopting an idea that President Trump had: ``Put a
cap, 120 percent.'' We will not pay more than that, what other
countries pay for the same medication.
President Trump put it in his blunt way: ``We are being suckers.''
We are putting a cap on that price. This will lower the cost of
prescription drugs over 10 years by a half a trillion dollars.
Finally, our government is standing up on behalf of consumers in not
protecting Pharma against unlimited price gouging.
And second, what is inspiring to me about this is the benefits go to
everyone. Employers in Vermont, they want their employees to have
healthcare, but those premiums keep going up and up and they have to
trade healthcare benefits for wages and salary increases.
So that means our employers are going to get the benefit of lower
premiums; our individuals are going to get the benefit of lower
premiums; and seniors, who have been hammered with co-pays and
deductibles, are going to get lower costs as well.
Individual drugs, too, you won't be getting killed on those, folks
with insulin and others. So let's pass this for Elijah.
Ms. SHALALA. Mr. Speaker, I reserve the balance of my time.
Mr. BURGESS. Mr. Speaker, I yield 3 minutes to the gentleman from
Washington State (Mr. Newhouse), previous member of the Rules Committee
and a valuable member of the Committee on Appropriations.
Mr. NEWHOUSE. Mr. Speaker, I thank my good friend from Texas for
yielding. I rise today in strong support of the underlying legislation,
H.R. 5083, the Farm Workforce Modernization Act.
This is a critical piece of legislation for my constituents,
certainly in Central Washington, but for farmers and ranchers across
the country in need of a stable and legal workforce.
I am grateful for my friend, Representative Lofgren, for including
Republicans in these negotiations and bringing together a diverse
bipartisan group of Members of Congress, agricultural stakeholders,
farmers and producers, labor unions and farmworker associations to
write a piece of legislation that will go a long way toward
[[Page H10039]]
providing certainty for our Ag industry.
The House has failed to address Ag labor reform since 1986. For the
last 30 years, the crisis facing farmers has only been exacerbated, and
the need for fixes has become even more clear.
Today, we have an opportunity to continue this process and bring
relief to farmers and ranchers, not just those I represent, but dairy
farmers in the Midwest, Wisconsin, Indiana, Ohio, Michigan and
Northeast, New York and Maine; the famous peach orchards of Georgia and
South Carolina; and certainly the orange groves in Texas and the salad
bowl of California and Arizona--all across the country.
Like past efforts, this bill may not be the perfect solution, but it
is a significant improvement over the status quo. This legislation
stabilizes our current workforce by implementing the first of its kind,
merit-based immigration program for agricultural workers who have spent
decades in our fields.
The bill streamlines our current H-2A program and reduces the
bureaucratic red tape for farmers. It addresses rising costs of guest
worker wages and implements E-Verify for the Ag industry, something
Republicans have been asking for since the rollout of the program.
Despite the progress this legislation makes, there is still work to
do. It does not address every sector of our Nation's Ag industry. We
still have to find a solution for our processors. We need to improve
the equitable housing options. There are many other aspects of our
broken immigration system we must work together to fix.
{time} 1315
A ``yes'' vote today on this bill is a vote to continue the process
and get this bill to the Senate.
I want to thank the staff, certainly Travis Martinez and Carrie
Meadows, but also David Shahoulian and Betsy Lawrence on Ms. Lofgren's
staff. Many people have put a lot of time into this effort.
Our farmers and ranchers desperately need relief. Men and women who
contribute to our ag industry need certainty. This bill is the first
step.
I urge my colleagues to vote for the underlying legislation and
encourage their input as we continue to perfect the bill and send it to
the President's desk.
Ms. SHALALA. Mr. Speaker, I yield 2 minutes to the gentleman from
Texas (Mr. Doggett).
Mr. DOGGETT. Mr. Speaker, for those insured who rely on insulin or
who are fortunate enough to win the lottery to have their drugs
selected to be negotiated, this is a valuable piece of legislation. But
for 30 million Americans who are uninsured, they are denied any
guarantee of lower prices.
Inexplicably, this rule rejects a proposal by me and 28 of our
colleagues to provide relief for the uninsured. It bars all of my
amendments to improve H.R. 3, including those that addressed outrageous
new drug launch prices; price spike protection, which price spikes are
occurring at an alarming rate, by the thousands; and ensuring
negotiation for those drugs where the taxpayers are actually picking up
the tab to finance the research that produces the drug.
Of all of these, the most troubling concerns the uninsured. USA Today
just published a powerful op-ed by Nicole Smith-Holt. It is entitled:
``My Son Died From Rationing Insulin. Democrats' Drug Pricing Plan
Still Wouldn't Help Him.'' She writes of her son, age 26, who aged out
of his parents' insurance and had a job with no benefits.
She expresses the same concern that a group of Michigan high
schoolers recently wrote me in a compelling letter that they are
raising money to help those who lack insurance buy their drugs, saying:
``Drug manufacturers should not be able to determine who does and who
does not get better. Everyone deserves to be healthy . . . .`'
And everyone deserves to be helped by our legislation, but some are
left out. My goal has never been to turn this bill to the right or to
the left, but to deal with those and provide assurances to those who
have been left out by it.
Under this legislation, it will still remain illegal, a violation of
Federal law, to negotiate lower drug prices on two-thirds of the
drugs----
The SPEAKER pro tempore. The time of the gentleman has expired.
Ms. SHALALA. Mr. Speaker, I yield an additional 30 seconds to the
gentleman from Texas.
Mr. DOGGETT. It remains illegal to negotiate on two-thirds of the
drugs that are covered by Medicare. Prescription drug price gouging,
enabled by government-approved monopolies without any restraint, is not
limited to one disease or one class of drugs.
The perfect should certainly not get in the way of the good in
drafting such legislation, but we should be doing more to deliver the
good we promised.
I reluctantly oppose this rule.
Mr. BURGESS. Mr. Speaker, I yield myself 30 seconds.
Mr. Speaker, I want to share a letter that I received. This is from a
woman who had lost her daughter to suicide following an episode of
severe postpartum depression. She writes:
After many long years of research and development, on 3/19,
calendar year 2019, the Food and Drug Administration approved
Zulresso, the first medicine to successfully treat moderate
to severe postpartum depression worldwide. It is a 60-hour IV
treatment, administered in a certified hospital setting. It
is effective in as little as 20 hours. Had this medicine been
available, I feel that my daughter would be alive today.
Mr. Speaker, I reserve the balance of my time.
Ms. SHALALA. Mr. Speaker, I yield 2 minutes to the gentlewoman from
Florida (Ms. Castor).
Ms. CASTOR of Florida. Mr. Speaker, I want to thank my colleague from
Florida (Ms. Shalala) for yielding time and, also, for her leadership
throughout the years in fighting to keep drug costs low. It really
matters to families all across this country.
I feel like shouting this from the top of the Capitol dome: We are
going to pass a bill that will allow Medicare to negotiate drug prices
in America.
This is kind of an all-American concept, isn't it, negotiate fair
prices?
But for too long, Big Pharma, these drug companies, have gouged
American families and consumers, and they have taken advantage of it,
haven't they? I mean, these prices are astronomical.
Families across America are often paying 4, 5, 10 times more the
amount for their prescriptions than families in other countries. That
is not right, and it is especially not right in this country where it
is the U.S. taxpayer who is often providing the funding for the basic
research to develop these drugs.
So let's all shout it from the Capitol dome, the very top: We are
going to allow--we are going to direct Medicare to negotiate prices to
bring the cost of prescription drugs down.
We are going to not just contain that in Medicare, but make sure that
it is spread, and those cost savings are realized for all of the
families who rely on private insurance.
And then, with the billions of dollars in savings, we are going to
improve Medicare. For a long time, Medicare has not provided
comprehensive benefits for vision, for hearing, for dental care. These
are fundamental health services.
So what a winning proposition for American families. And I am so
proud that it is the Democrats and our new majority that can deliver on
this promise for the people.
Lower drug costs now.
Mr. BURGESS. Mr. Speaker, I yield myself such time as may consume.
If we defeat the previous question, Republicans will amend the rule
immediately to consider H.R. 2207, the Protect Medical Innovation Act
of 2019. This bill, which now has 256 bipartisan cosponsors, will
repeal the excise tax on medical devices that is set to go into effect
January 1, 2020.
Mr. Speaker, I ask unanimous consent to insert the text of this
amendment in the Record, along with extraneous material, immediately
prior to the vote on the previous question.
The SPEAKER pro tempore. Is there objection to the request of the
gentleman from Texas?
There was no objection.
Mr. BURGESS. Mr. Speaker, I yield 2 minutes to the gentlewoman from
Indiana (Mrs. Brooks), my good friend, a valuable member of the Energy
and Commerce Committee.
Mrs. BROOKS of Indiana. Mr. Speaker, if we defeat the previous
question, we can move to pass H.R. 2207.
Why is it so important that we repeal this disastrous medical device
tax? Since 2013, when I came to Congress, my colleagues and I across
the aisle
[[Page H10040]]
have worked in a bipartisan way to delay and, ultimately, defeat this
disastrous tax.
And why is that so important? It is not just about the economics of a
tax; it is about patients. This is about innovation for patients, and
higher taxes mean fewer innovations will be developed for patients.
Fewer lives will be saved because, when we tax this critical industry,
it will make it harder for them to come up with and fund the next
lifesaving technology.
Tell that to the over a million people a year, worldwide, who receive
implants like pacemakers. These folks rely on these lifesaving devices.
So many of the innovations will not come to market.
Medical devices allow patients to undergo fewer intensive procedures,
with shorter hospitalizations and rehabilitation time, which ultimately
lowers the overall cost of patient care.
Beyond patient care, this is an amazing industry; and if we tax these
businesses, jobs will be lost. We already know that, when the tax was
in place, 29,000 jobs were lost in this industry. These are high-paying
jobs in States across the country.
Indiana is one of the top States in the country to have these types
of medical device jobs. These pay 30 percent higher. The degree of
expertise and the skill of these workers, particularly in the area of
research and development and manufacturing, is unbelievable. And these
people work day in and day out to provide better medical devices to
consumers, not just here in this country, but around the globe.
So reinstating this medical device tax, which will take place on
January 1 of 2020, will hurt the success not just of these businesses,
but it will roll back innovations and stifle R&D of these lifesaving
and life-altering medical advances.
We have a chance, with 256 cosponsors, to stand together and repeal
this tax. I urge this body to pass the repeal of the medical device
tax.
Ms. SHALALA. Mr. Speaker, I yield 1 minute to the gentlewoman from
Massachusetts (Mrs. Trahan).
Mrs. TRAHAN. Mr. Speaker, I want to thank my colleague from Florida
for yielding.
Today, the House considers historic legislation to lower prescription
drug prices and deliver a transformational expansion to Medicare under
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act of 2019.
The namesake of this bill inspired many Members of this body, myself
included, to act boldly on behalf of working families like the one I
grew up in. It is time to flip the status quo on a system that has
pocketed billions off the backs of patients like my dad who suffer from
chronic diseases like MS.
I am proud to have championed a provision which added a critical
lever of transparency and accountability by requiring a GAO study on
the negotiation program, essentially ensuring that there is no unfair
manipulation or gaming at play. While I regret that my amendment to
support baseline knowledge of addiction among prescribers was not made
in order, I look forward to supporting this important bill.
I am grateful to leadership, my colleagues, and the committees of
jurisdiction for bringing us all here to this point today.
Mr. BURGESS. Mr. Speaker, I yield 1\1/2\ minutes to the gentleman
from Indiana (Mr. Baird) to speak on the amendment as part of the
defeat of the previous question.
Mr. BAIRD. Mr. Speaker, I thank the ranking member for yielding.
Mr. Speaker, I rise today in support of the 60,000 direct and
indirect jobs that the medical device industry brings to my home State.
The last 4 years, Congress has worked together to continually suspend
the medical device tax because they know that it doesn't make sense.
This tax is a bane to innovation; it damages our manufacturing sector;
it raises healthcare prices; and it hurts high-paying jobs.
What our medical device industry needs more than anything is
certainty. There has been enough upheaval in our healthcare system over
the last decade to last us a lifetime.
Let's show our support for the hardworking Americans, the good jobs,
the patients, and the employers and permanently repeal this tax.
Ms. SHALALA. Mr. Speaker, I yield 2 minutes to the gentleman from
California (Mr. Correa).
Mr. CORREA. Mr. Speaker, I rise in strong support of the Farm
Workforce Modernization Act of 2019.
I want to thank Representative Lofgren for her leadership, as well as
colleagues on both sides of the aisle, for making this vote today
happen. It will be a historical vote.
California, my home State, is our Nation's bread basket; yet, over 40
percent of California's farms don't have the workforce they need to
feed our population. The same is true for many farms across the country
that depend on skilled immigrant farmworkers.
These men and women work in our fields to plant, care, and harvest
our produce that feeds our families, both in the U.S. and
internationally. They do good work, good honest work, but live in an
uncertain situation.
Farm owners and farmworkers agree that this reform is desperately
needed. This bill offers a stable workforce for our farmers, who need
to compete in the global food markets, and provides an earned legal
status for farmworkers.
I urge passage of H.R. 5038.
Mr. BURGESS. Mr. Speaker, I yield 1 minute to the gentleman from
Indiana (Mr. Bucshon) to continue our speakers on the defeat of the
previous question and in support of their amendment.
Mr. BUCSHON. Mr. Speaker, there are over 150 medical device companies
in the State of Indiana representing more than 20,000 jobs. These are
high-paying, stable jobs, with more than $1 billion in Indiana
payrolls. But, more importantly, they provide lifesaving products for
the American consumer.
As a physician, I know the importance of the innovation and the
technological advances these companies provide, and the medical device
tax is an onerous tax that is helping to stymie this innovation and
technology.
{time} 1330
By defeating the previous question, we can bring up H.R. 2207, the
Protect Medical Innovation Act of 2019, and finally repeal permanently
the onerous excise tax on the sale of medical devices in our country.
This will allow for more treatments, and this will allow for more
cures.
Ms. SHALALA. Mr. Speaker, I yield 2 minutes to the gentlewoman from
California (Ms. Lofgren).
Ms. LOFGREN. Mr. Speaker, I want to make a few additional comments on
the Farm Workforce Modernization Act since the gentlewoman from Florida
had a little bit of time to provide.
There have been some who have criticized, I think incorrectly, the
bill, that it does not actually stabilize wages in the H-2A program.
That is incorrect.
The bargain that was made by the United Farm Workers union and the
various employer groups was to: first, freeze wages for 1 year; second,
to limit how fast wages could rise to 3.25 percent or how low to 1.5
percent; and also, to preclude changes in the middle of a contract, so
there would be stability.
I just wanted to get that issue on the table. People who
misunderstand it will be relieved to know that that is not correct.
I want to address another issue, which has to do with the
legalization provision. We have several million farmworkers in the
United States today. Half of them don't have their proper papers. They
are living in a state of fear.
I was out in the Central Valley recently. These are hardworking
people who have been here for decades in some cases. There is no line
for them to get into to get legal. They are so afraid that they are
afraid to go to mass.
This bill allows them to apply for a temporary visa, an agricultural
worker visa that is renewable. It allows them to go back and forth if
they need to go to a funeral in their country of birth. It allows them
to work legally.
After an extended period of time, if they want, they can apply to
become legal permanent residents of the United States, or they can just
stay on their temporary visas. Their families are included because we
should not be in the position of breaking up hardworking families.
The SPEAKER pro tempore. The time of the gentlewoman has expired.
Ms. SHALALA. Mr. Speaker, I yield an additional 30 seconds to the
gentlewoman from California.
Ms. LOFGREN. Mr. Speaker, I would like to note that this bill is the
product of a lot of time. It was introduced
[[Page H10041]]
in October. It was marked up in the Judiciary Committee before
Thanksgiving, and here we are today, not that far from Christmas,
finally, hopefully, passing it.
We have been in discussions with various Senators. There is nothing
ever for sure with the United States Senate, but I will say there is a
recognition and an interest that doing nothing is not acceptable for
farmers or for farmworkers.
I hope we can pass this bill today.
Mr. BURGESS. Mr. Speaker, I yield 2 minutes to the gentleman from
Indiana (Mr. Pence) to continue to speak on the amendment that we will
offer if we defeat the previous question,
Mr. PENCE. Mr. Speaker, I thank the gentleman for yielding. As
ranking member of the House Energy and Commerce Subcommittee on Health,
I thank my colleague, Dr. Burgess, for his steadfast leadership on this
issue.
Mr. Speaker, I am proud to join 255 of my colleagues as a cosponsor
of H.R. 2207, the Protect Medical Innovation Act. I rise today to
remind my fellow Members that time is running out. We must repeal the
medical device tax before it goes into effect on January 1, 2020.
This bill has broad bipartisan support from Members in both Chambers
who recognize the detrimental impact this tax has on constituents who
rely on lifesaving medical devices or are employed by the industry.
If Congress fails to act this year, the seemingly small 2.3 percent
excise tax would have a significant impact on patients and the
healthcare industry.
The medical device industry employs 400,000 hardworking Americans,
including 20,000 Hoosiers. When the medical device tax was in effect,
nearly 20,000 industry jobs were lost nationwide.
Eighty percent of these medical manufacturing companies are small
businesses that need certainty. They need certainty in order to
continue their research and investment in critical lifesaving medical
innovations.
This is a tax on innovation and competitiveness, a tax on patients,
and a tax on working families. It is time to end this job-killing tax
once and for all.
I urge my fellow Members to vote ``no'' on the previous question so
we can support H.R. 2207.
Mr. BURGESS. Mr. Speaker, may I inquire as to how much time I have
remaining.
The SPEAKER pro tempore. The gentleman from Texas has 5\1/2\ minutes.
The gentlewoman from Florida has 6\3/4\ minutes.
Mr. BURGESS. Mr. Speaker, I yield myself the balance of my time.
Mr. Speaker, we have been hearing from our colleagues from Indiana
about the excise tax on medical devices and how important it is to
repeal that excise tax on medical devices.
That tax has been delayed several times but does go into effect
January 1. It is a 2.8 percent excise tax on gross receipts. We are
talking in H.R. 3 about a 95 percent excise tax. They are talking about
the number of jobs that have been killed with a 2.8 percent Federal
excise tax. How many jobs are going to be lost with a 95 percent excise
tax?
Again, as I said earlier, this is not a good faith negotiation with
the Secretary of Health and Human Services. This is akin to a hostage
situation because the threat of a 95 percent excise tax hangs over that
discussion.
We have heard a lot about innovation. Let me share with you an
excerpt from a letter that I received from a constituent after the
introduction of H.R. 3. The letter says: ``I started taking
antidepressants when I was 15. Since then, I have been hospitalized
three different times for attempts at suicide. Now I am at a place
where I have found the medication that works for me; it is literally
lifesaving. This medication is only possible through years of careful
research and investment and in good supply because of a free market.
``If we had allowed a bill like H.R. 3 to pass into law previously,
then the medications that have helped me might not exist. I cannot
imagine a world where people just like me might go without the proper
medication due to government overreach.''
The story is repeated over and over again. Mr. Speaker, Congress
passed at the end of the session in calendar year 2016 the last bill
signed into law by President Obama, the 21st Century Cures Act.
Mr. Speaker, since the time that bill was signed into law, it really
has been impressive the number of new things that are coming onto the
market and those new things that are just over the horizon.
This bill, H.R. 3, strips the ability for the 21st Century Cures Act
to deliver on the promise. But here is the good news. The Rules
Committee, in its wisdom, made available an amendment in the nature of
a substitute.
I have discussed H.R. 19 in some detail. The amendment in the nature
of a substitute will be the text of H.R. 19 so Members will have an
opportunity to vote for bipartisan consensus agreements that will lower
drug prices now, that will protect innovation in the future, and that,
most importantly, could be signed into law before the end of the year.
Think about it. This is a deliverable that we have within our power
to bring to the American people. We should not give up on that chance.
I have been speaking against H.R. 3. The NDAA, which is also included
in this legislation, I do support. I cannot support the guest worker
bill.
Mr. Speaker, I urge a ``no'' vote on the previous question. Let's
take up the amendment about the excise tax on medical devices, and I
yield back the balance of my time.
Ms. SHALALA. Mr. Speaker, I yield myself the balance of my time.
Mr. Speaker, we have heard doomsday predictions from my colleagues on
the other side of the aisle that our Nation's drug innovation will be
decimated by this bill. Mr. Speaker, if I thought this bill would slow
down or eliminate our brilliant biomedical research and development
enterprise, I would not support it.
Nothing could be further from the truth. The truth is that much of
our drug innovation starts with our own government-funded research paid
for by the taxpayers either at the National Institutes of Health or at
our great research universities, two of which I have led.
This bill provides critical additional investments in NIH. $10
billion will extend research investments in projects like Cancer
Moonshot to accelerate cancer research and make more therapies
available to more patients. It will also help fund innovation and
research for rare diseases and fighting antimicrobial resistance, which
currently kills 35,000 Americans per year.
This bill also makes explicit that pharmaceutical companies should be
able to recoup the costs of research and development and still make a
profit. Nine out of 10 Big Pharma companies spend more on marketing,
sales, and overhead than research. Maybe they won't be making as big of
a profit as they currently do because they will no longer be able to
take the American people to the cleaners, but they will make a
substantial profit.
Medicare will continue to cover all the drugs they cover today so
that patients' choices will not be limited. Rather, patients' choices
will be expanded. Patients will no longer be leaving drugs behind at
the pharmacy counter because they can't afford them.
It is time to end sky-high drug prices. It is also time to reform
Medicare benefits for the 21st century. This bill does exactly that by
finally adding vision, dental, and hearing benefits to the Medicare
program.
Seniors have been asking for this for a long time, and the quality of
life of millions of Medicare beneficiaries will improve with access to
these benefits.
I also look forward to the passage of the Farm Workforce
Modernization Act and the conference report for the NDAA. These are
bipartisan pieces of legislation that will improve our national
security and the lives of families and workers across this Nation.
Mr. Speaker, I urge a ``yes'' vote on the rule and the previous
question.
The material previously referred to by Mr. Burgess is as follows:
Amendment to House Resolution 758
At the end of the resolution, add the following:
Sec. 13. Immediately upon adoption of this resolution, the
House shall proceed to the consideration in the House of the
bill (H.R. 2207) to amend the Internal Revenue Code of 1986
to repeal the excise tax on medical devices. All points of
order against consideration of the bill are waived. The bill
shall be considered as read. All points of order against
provisions in the bill are waived. The previous question
shall be considered as ordered on the bill and on any
amendment
[[Page H10042]]
thereto to final passage without intervening motion except:
(1) one hour of debate equally divided and controlled by the
chair and ranking minority member of the Committee on Ways
and Means; and (2) one motion to recommit.
Sec. 14. Clause 1(c) of rule XIX shall not apply to the
consideration of H.R. 2207.
Ms. SHALALA. Mr. Speaker, I yield back the balance of my time, and I
move the previous question on the resolution.
The SPEAKER pro tempore. The question is on ordering the previous
question.
The question was taken; and the Speaker pro tempore announced that
the ayes appeared to have it.
Mr. BURGESS. Mr. Speaker, on that I demand the yeas and nays.
The yeas and nays were ordered.
The SPEAKER pro tempore. Pursuant to clause 9 of rule XX, this 15-
minute vote on ordering the previous question will be followed by 5-
minute votes on:
Adoption of the resolution, if ordered; and
The motion to table the motion to reconsider H.R. 729.
The vote was taken by electronic device, and there were--yeas 227,
nays 189, not voting 14, as follows:
[Roll No. 668]
YEAS--227
Adams
Aguilar
Allred
Axne
Bass
Beatty
Bera
Beyer
Bishop (GA)
Blumenauer
Blunt Rochester
Bonamici
Boyle, Brendan F.
Brindisi
Brown (MD)
Brownley (CA)
Bustos
Butterfield
Carbajal
Cardenas
Carson (IN)
Cartwright
Case
Casten (IL)
Castor (FL)
Castro (TX)
Chu, Judy
Cicilline
Cisneros
Clark (MA)
Clarke (NY)
Clay
Cleaver
Clyburn
Cohen
Connolly
Cooper
Correa
Costa
Courtney
Cox (CA)
Craig
Crist
Crow
Cuellar
Cunningham
Davids (KS)
Davis (CA)
Davis, Danny K.
Dean
DeFazio
DeGette
DeLauro
DelBene
Delgado
Demings
DeSaulnier
Deutch
Dingell
Doggett
Doyle, Michael F.
Engel
Escobar
Eshoo
Espaillat
Evans
Finkenauer
Fletcher
Foster
Frankel
Fudge
Gallego
Garamendi
Garcia (IL)
Garcia (TX)
Golden
Gomez
Gonzalez (TX)
Gottheimer
Green, Al (TX)
Grijalva
Haaland
Harder (CA)
Hastings
Hayes
Heck
Higgins (NY)
Himes
Horn, Kendra S.
Horsford
Houlahan
Hoyer
Huffman
Jackson Lee
Jayapal
Jeffries
Johnson (GA)
Johnson (TX)
Kaptur
Keating
Kelly (IL)
Kennedy
Khanna
Kildee
Kilmer
Kim
Kind
Kirkpatrick
Krishnamoorthi
Kuster (NH)
Lamb
Langevin
Larsen (WA)
Larson (CT)
Lawrence
Lawson (FL)
Lee (CA)
Lee (NV)
Levin (CA)
Levin (MI)
Lewis
Lipinski
Loebsack
Lofgren
Lowenthal
Lowey
Lujan
Luria
Lynch
Malinowski
Maloney, Carolyn B.
Maloney, Sean
Matsui
McAdams
McBath
McCollum
McEachin
McGovern
McNerney
Meeks
Meng
Moore
Morelle
Moulton
Mucarsel-Powell
Murphy (FL)
Nadler
Napolitano
Neal
Neguse
Norcross
O'Halleran
Ocasio-Cortez
Omar
Pallone
Panetta
Pappas
Pascrell
Payne
Perlmutter
Peters
Peterson
Phillips
Pingree
Pocan
Pressley
Price (NC)
Quigley
Raskin
Rice (NY)
Richmond
Rose (NY)
Rouda
Roybal-Allard
Ruiz
Ruppersberger
Rush
Ryan
Sanchez
Sarbanes
Scanlon
Schakowsky
Schiff
Schneider
Schrader
Schrier
Scott (VA)
Scott, David
Sewell (AL)
Shalala
Sherman
Sherrill
Simpson
Sires
Slotkin
Smith (WA)
Soto
Spanberger
Speier
Stanton
Stevens
Suozzi
Swalwell (CA)
Takano
Thompson (CA)
Thompson (MS)
Titus
Tlaib
Tonko
Torres (CA)
Torres Small (NM)
Trahan
Trone
Underwood
Van Drew
Vargas
Veasey
Vela
Velazquez
Visclosky
Wasserman Schultz
Waters
Watson Coleman
Welch
Wild
Wilson (FL)
Yarmuth
NAYS--189
Abraham
Allen
Amash
Amodei
Armstrong
Arrington
Babin
Bacon
Baird
Balderson
Banks
Barr
Bergman
Biggs
Bilirakis
Bishop (NC)
Bishop (UT)
Bost
Brady
Brooks (AL)
Brooks (IN)
Buchanan
Buck
Bucshon
Budd
Burchett
Burgess
Byrne
Calvert
Carter (GA)
Carter (TX)
Chabot
Cheney
Cline
Cloud
Cole
Collins (GA)
Comer
Conaway
Cook
Crawford
Crenshaw
Curtis
Davidson (OH)
Davis, Rodney
DesJarlais
Diaz-Balart
Duncan
Dunn
Emmer
Estes
Ferguson
Fitzpatrick
Fleischmann
Flores
Fortenberry
Foxx (NC)
Fulcher
Gaetz
Gallagher
Gianforte
Gibbs
Gohmert
Gonzalez (OH)
Gooden
Granger
Graves (GA)
Graves (LA)
Graves (MO)
Green (TN)
Griffith
Grothman
Guest
Guthrie
Hagedorn
Harris
Hartzler
Hern, Kevin
Herrera Beutler
Hice (GA)
Higgins (LA)
Hill (AR)
Holding
Hollingsworth
Hudson
Huizenga
Hurd (TX)
Johnson (LA)
Johnson (OH)
Johnson (SD)
Jordan
Joyce (OH)
Joyce (PA)
Katko
Keller
Kelly (MS)
Kelly (PA)
King (IA)
King (NY)
Kinzinger
Kustoff (TN)
LaHood
Lamborn
Latta
Lesko
Long
Loudermilk
Lucas
Luetkemeyer
Marchant
Marshall
Massie
Mast
McCarthy
McCaul
McClintock
McHenry
McKinley
Meadows
Meuser
Miller
Mitchell
Moolenaar
Mooney (WV)
Mullin
Murphy (NC)
Nunes
Olson
Palazzo
Palmer
Pence
Perry
Posey
Ratcliffe
Reed
Reschenthaler
Rice (SC)
Riggleman
Roby
Rodgers (WA)
Roe, David P.
Rogers (AL)
Rogers (KY)
Rose, John W.
Rouzer
Roy
Rutherford
Scalise
Schweikert
Scott, Austin
Sensenbrenner
Shimkus
Smith (MO)
Smith (NE)
Smith (NJ)
Smucker
Spano
Stauber
Stefanik
Steil
Steube
Stewart
Stivers
Taylor
Thompson (PA)
Thornberry
Timmons
Tipton
Turner
Upton
Wagner
Walberg
Walden
Walorski
Waltz
Watkins
Weber (TX)
Webster (FL)
Wenstrup
Westerman
Williams
Wilson (SC)
Wittman
Womack
Woodall
Wright
Yoho
Young
Zeldin
NOT VOTING--14
Aderholt
Barragan
Gabbard
Gosar
Hunter
LaMalfa
Lieu, Ted
Newhouse
Norman
Porter
Rooney (FL)
Serrano
Walker
Wexton
{time} 1412
Mr. ARRINGTON changed his vote from ``yea'' to ``nay.''
Mr. ROSE of New York changed his vote from ``nay'' to ``yea.''
So the previous question was ordered.
The result of the vote was announced as above recorded.
personal explanation
Ms. PORTER. Mr. Speaker, I was present but my vote did not register
on rollcall No. 668 on December 11, 2019 due to a machine malfunction.
I voted by inserting my machine card into the machine with several
minutes remaining. The system apparently did not record my ``yea''
vote. I was present on the House floor for the duration of the vote.
Had my vote been recorded, it would have been recorded as ``yea.''
The SPEAKER pro tempore (Mr. Panetta). The question is on the
resolution.
The question was taken; and the Speaker pro tempore announced that
the ayes appeared to have it.
Mr. BURGESS. Mr. Speaker, on that I demand the yeas and nays.
The yeas and nays were ordered.
The SPEAKER pro tempore. This is a 5-minute vote.
The vote was taken by electronic device, and there were--yeas 222,
nays 190, not voting 18, as follows:
[Roll No. 669]
YEAS--222
Adams
Aguilar
Allred
Axne
Bass
Beatty
Bera
Beyer
Bishop (GA)
Blumenauer
Blunt Rochester
Bonamici
Boyle, Brendan F.
Brindisi
Brown (MD)
Brownley (CA)
Bustos
Butterfield
Carbajal
Cardenas
Cartwright
Case
Casten (IL)
Castor (FL)
Castro (TX)
Chu, Judy
Cicilline
Cisneros
Clark (MA)
Clarke (NY)
Clay
Cleaver
Clyburn
Cohen
Connolly
Cooper
Correa
Costa
Courtney
Cox (CA)
Craig
Crist
Crow
Cuellar
Cunningham
Davids (KS)
Davis (CA)
Davis, Danny K.
Dean
DeFazio
DeGette
DeLauro
DelBene
Delgado
Demings
DeSaulnier
Deutch
Dingell
Doyle, Michael F.
Engel
Escobar
Eshoo
Espaillat
Evans
Finkenauer
Fletcher
Foster
Frankel
Fudge
Gallego
Garamendi
Garcia (IL)
Garcia (TX)
Golden
Gomez
Gonzalez (TX)
Gottheimer
Green, Al (TX)
Grijalva
Haaland
Harder (CA)
Hastings
Hayes
Heck
Higgins (NY)
Himes
Horn, Kendra S.
Horsford
Houlahan
Hoyer
Huffman
Jackson Lee
Jayapal
Jeffries
Johnson (GA)
Johnson (TX)
Kaptur
Keating
Kelly (IL)
Kennedy
Kildee
Kilmer
Kim
Kind
Kirkpatrick
Krishnamoorthi
Kuster (NH)
Lamb
Langevin
Larsen (WA)
Larson (CT)
Lawrence
Lawson (FL)
Lee (CA)
Lee (NV)
Levin (CA)
Levin (MI)
Lewis
Lipinski
Loebsack
Lofgren
Lowenthal
Lowey
Lujan
Luria
Lynch
Malinowski
Maloney, Carolyn B.
Maloney, Sean
Matsui
McBath
McCollum
McEachin
McGovern
McNerney
Meeks
Meng
Moore
Morelle
Moulton
Mucarsel-Powell
Murphy (FL)
Nadler
Napolitano
Neal
Neguse
Norcross
O'Halleran
Omar
Pallone
Panetta
Pappas
Pascrell
Payne
Perlmutter
Peterson
Phillips
Pingree
Pocan
Porter
Pressley
Price (NC)
Quigley
Raskin
Rice (NY)
Richmond
Rose (NY)
Rouda
[[Page H10043]]
Roybal-Allard
Ruiz
Rush
Ryan
Sanchez
Sarbanes
Scanlon
Schakowsky
Schiff
Schneider
Schrader
Schrier
Scott (VA)
Scott, David
Sewell (AL)
Shalala
Sherman
Sherrill
Simpson
Sires
Slotkin
Smith (WA)
Soto
Spanberger
Speier
Stanton
Stevens
Suozzi
Swalwell (CA)
Takano
Thompson (CA)
Thompson (MS)
Titus
Tlaib
Tonko
Torres (CA)
Torres Small (NM)
Trahan
Trone
Underwood
Van Drew
Vargas
Veasey
Vela
Velazquez
Visclosky
Wasserman Schultz
Waters
Watson Coleman
Welch
Wexton
Wild
Wilson (FL)
Yarmuth
NAYS--190
Abraham
Allen
Amash
Amodei
Armstrong
Arrington
Babin
Bacon
Baird
Balderson
Banks
Barr
Bergman
Biggs
Bilirakis
Bishop (NC)
Bishop (UT)
Bost
Brady
Brooks (AL)
Brooks (IN)
Buchanan
Buck
Bucshon
Budd
Burchett
Burgess
Byrne
Calvert
Carter (GA)
Carter (TX)
Chabot
Cline
Cloud
Cole
Collins (GA)
Comer
Conaway
Cook
Crawford
Crenshaw
Curtis
Davidson (OH)
Davis, Rodney
DesJarlais
Diaz-Balart
Doggett
Duncan
Dunn
Emmer
Estes
Ferguson
Fitzpatrick
Fleischmann
Flores
Fortenberry
Foxx (NC)
Fulcher
Gaetz
Gallagher
Gianforte
Gohmert
Gonzalez (OH)
Gooden
Gosar
Granger
Graves (GA)
Graves (LA)
Graves (MO)
Green (TN)
Griffith
Grothman
Guest
Guthrie
Hagedorn
Harris
Hartzler
Hern, Kevin
Herrera Beutler
Hice (GA)
Higgins (LA)
Holding
Hollingsworth
Hudson
Huizenga
Hurd (TX)
Johnson (LA)
Johnson (OH)
Johnson (SD)
Jordan
Joyce (OH)
Katko
Keller
Kelly (MS)
Kelly (PA)
Khanna
King (NY)
Kinzinger
Kustoff (TN)
LaHood
Lamborn
Latta
Lesko
Long
Loudermilk
Lucas
Luetkemeyer
Marchant
Marshall
Massie
Mast
McAdams
McCarthy
McCaul
McClintock
McHenry
McKinley
Meadows
Meuser
Miller
Mitchell
Moolenaar
Mooney (WV)
Mullin
Murphy (NC)
Nunes
Ocasio-Cortez
Olson
Palazzo
Palmer
Pence
Perry
Peters
Posey
Ratcliffe
Reed
Reschenthaler
Rice (SC)
Riggleman
Roby
Rodgers (WA)
Roe, David P.
Rogers (AL)
Rogers (KY)
Rose, John W.
Rouzer
Roy
Scalise
Schweikert
Scott, Austin
Sensenbrenner
Shimkus
Smith (MO)
Smith (NE)
Smith (NJ)
Smucker
Spano
Stauber
Stefanik
Steil
Steube
Stewart
Stivers
Taylor
Thompson (PA)
Thornberry
Timmons
Tipton
Turner
Upton
Wagner
Walberg
Walden
Walker
Walorski
Waltz
Watkins
Weber (TX)
Webster (FL)
Wenstrup
Westerman
Williams
Wilson (SC)
Wittman
Womack
Woodall
Wright
Yoho
Young
Zeldin
NOT VOTING--18
Aderholt
Barragan
Carson (IN)
Cheney
Gabbard
Gibbs
Hill (AR)
Hunter
Joyce (PA)
King (IA)
LaMalfa
Lieu, Ted
Newhouse
Norman
Rooney (FL)
Ruppersberger
Rutherford
Serrano
{time} 1418
So the resolution was agreed to.
The result of the vote was announced as above recorded.
Stated against:
Mr. JOYCE of Pennsylvania. Mr. Speaker, I was unavoidably detained.
Had I been present, I would have voted ``nay'' on rollcall No. 669.
Ms. CHENEY. Mr. Speaker, I was unavoidably detained. Had I been
present, I would have voted ``nay'' on rollcall No. 669.
The SPEAKER pro tempore. Without objection, a motion to reconsider is
laid on the table.
Mr. HARRIS. I object.
The SPEAKER pro tempore. Objection is heard.
____________________